Received Mar 20, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 2 | Unknown | PO / MO |
Patient took two doses of Vivotif and missed to receive third dose; Case reference number US-BN-2024-002043 is a spontaneous case initially received from a consumer via Communication (reference number: USBAV24-1342) on 11-Jun-2024 and concerns a female patient of unknown age. The patient's medical history and concomitant medication were not provided. On 06-Jun-2024, the patient took the first dose of Vivotif (batch number: unknown) at unknown dose, via oral use, prior to travel on 27 Jun 2024. On 08-Jun-2024, two days after the first dose, the patient took the second dose of Vivotif (batch number: unknown) at unknown dose, via oral use. As reported, patient took two doses of Vivotif and missed to receive third dose (explicitly coded as 'Inappropriate schedule of vaccine administered'). At the time of the initial report, it was unknown if the patient experienced any adverse event Vivotif. Non-significant follow up was downloaded from VAERS on 09-May-2025 included new reference number Administrative update performed within the case: Worldwide Unique Case Identification Number (WWID) updated from US-20240611-232ced to US-BAVARIAN NORDIC A/S-US-BN-2024-002043, in accordance with ICH guidance on WWID formatting; Reporter's Comments: A female patient of unknown age took two doses of Vivotif and missed to receive third dose, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse event Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication were not provided. Inappropriate schedule of product administration has been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A female patient of unknown age took two doses of Vivotif and missed to receive third dose, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse event Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication were not provided. Inappropriate schedule of product administration has been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None.